BAM Wealth Management Adds $1.09M Stake in Eli Lilly for 0.8% Portfolio
Third-quarter filings show BAM Wealth Management acquired 1,424 Eli Lilly shares for about $1.09 million, making it the firm’s 25th-largest position at 0.8% of assets and bolstering an 82.5% institutional ownership base. Major analysts now assign a consensus Buy rating with an average price target of $1,174.61.
1. BAM Wealth Management LLC Builds a New $1.09 Million Position in Eli Lilly
In its latest SEC filing, BAM Wealth Management LLC disclosed the acquisition of 1,424 shares of Eli Lilly during the third quarter, representing roughly $1,087,000 of investment. This stake now accounts for approximately 0.8% of BAM’s total portfolio assets, making Eli Lilly its 25th largest holding. The move highlights growing institutional confidence in the pharmaceutical leader’s growth trajectory and pipeline prospects.
2. Research Firms Update Price Targets and Ratings
Five major research houses issued fresh outlooks over the past two months. Bank of America trimmed its target from $1,286 to $1,268 while maintaining a Buy view on December 15. Goldman Sachs lifted its target from $951 to $1,145 and reiterated a Buy rating on the same date. Earlier, CICC Research raised its target from $801 to $1,060 with a Neutral stance on November 13, and Berenberg Bank upped its target from $830 to $950, assigning a Hold rating on December 2. On January 6, UBS Group initiated coverage with a Buy rating and a $1,250 objective. At present, four analysts rate the stock Strong Buy, eighteen rate it Buy and four rate it Hold, yielding a consensus Buy recommendation and an average target of $1,174.61.
3. Q3 Earnings Outperform and FY 2025 EPS Guidance Raised
In its Q3 report released on October 30, Eli Lilly delivered earnings per share of $7.02, surpassing consensus estimates by $0.60. Revenue reached $17.60 billion, beating forecasts by $1.51 billion and marking a 53.9% year-over-year increase. The company achieved a net margin of 30.99% and generated a 109.52% return on equity. Capitalizing on robust momentum, management set full-year 2025 EPS guidance in a range of $23.00 to $23.70, with analysts currently forecasting $23.48.
4. Quarterly Dividend Hiked to $1.73, Strengthening Yield Profile
Eli Lilly’s board approved a quarterly dividend increase to $1.73 per share, payable on March 10 to shareholders of record as of February 13. This represents a 15.3% rise from the prior $1.50 payout and annualizes to $6.92 per share, reflecting a yield near 0.60%. With a dividend payout ratio of 29.35%, the company balances capital returns with continued reinvestment in R&D and global expansion initiatives.